{"id":"NCT00723450","sponsor":"GlaxoSmithKline","briefTitle":"Lamictal as Add-on Treatment for Bipolar I Disorder in Pediatric Patients","officialTitle":"The Evaluation of Lamictal as an Add-on Treatment for Bipolar I Disorder in Children and Adolescents, 10 to 17 Years of Age","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-07","primaryCompletion":"2013-08","completion":"2013-08","firstPosted":"2008-07-28","resultsPosted":"2014-06-04","lastUpdate":"2017-01-09"},"enrollment":301,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Bipolar Disorder"],"interventions":[{"type":"DRUG","name":"lamictal","otherNames":[]}],"arms":[{"label":"placebo","type":"PLACEBO_COMPARATOR"},{"label":"lamictal","type":"EXPERIMENTAL"}],"summary":"The study will be a multi-center, parallel, group, placebo control, double-blind, randomized controlled trial of lamictal as add-on maintenance treatment in pediatric outpatients (aged 10 to 17 years) diagnosed with Bipolar I disorder. The study consists of 4 phases: Screen (approximately 2 weeks), Open label phase (up to 18 weeks), Randomized phase (up to 36 weeks) and Taper and follow-up phase (up to 4 weeks).","primaryOutcome":{"measure":"Time From Randomization to the Occurrence of a Bipolar Event (TOBE)","timeFrame":"From randomization until Week 36","effectByArm":[{"arm":"Placebo","deltaMin":50,"sd":3.8},{"arm":"Lamotrigine","deltaMin":155,"sd":14.7}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0717"}]},"eligibility":{"minAge":"10 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":10},"locations":{"siteCount":46,"countries":["United States"]},"refs":{"pmids":["26598477"],"seeAlso":["https://www.clinicalstudydatarequest.com"]},"adverseEventsSummary":{"seriousAny":{"events":19,"n":298},"commonTop":["Headache","Abdominal pain upper","Nausea","Oropharyngeal pain","Nasopharyngitis"]}}